- ···
- ···
- Data & APIs
- ···
- Events
- ···
- Marketfy
- ···
- Premarket Prep
- ···
- ···
- Contribute
- ···
Recent Quotes
You have no recent quotes
Range
0.71 - 0.73
Vol / Avg.
311.2K/2.3M
Div / Yield
-
52 Wk
0.29 - 3.62
Mkt Cap
86.2M
Payout Ratio
-
Open
0.72
P/E
-
EPS
-0.02
Shares
121.2M
Outstanding
121.2M
Total Float
121.2M
Benzinga - Jun 9, 2021, 12:24PM
Benzinga - May 17, 2021, 10:12AM
Benzinga - May 17, 2021, 8:11AM
Benzinga - May 13, 2021, 9:33AM
Benzinga - May 13, 2021, 8:05AM
Benzinga - May 6, 2021, 8:21AM
Benzinga - May 5, 2021, 8:09AM
Benzinga - Apr 26, 2021, 11:33AM
Benzinga - Mar 26, 2021, 11:43AM
Benzinga - Mar 25, 2021, 8:07AM
Benzinga - Mar 22, 2021, 4:07PM
Benzinga - Mar 15, 2021, 9:11AM
Benzinga - Mar 15, 2021, 9:01AM
Benzinga - Mar 15, 2021, 8:18AM
Benzinga - Mar 11, 2021, 8:15AM
Benzinga - Feb 19, 2021, 1:26PM
Benzinga - Feb 17, 2021, 5:54AM
Benzinga - Feb 16, 2021, 5:21PM
load more
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.
Earnings
see more| Q2 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2021-08-05 | ||||||
| REV | |||||||
| Q1 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.020 | ||||||
| REV | 600.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Related Companies
| Ticker | Company | Price | Change | Chg % | Mkt Cap | |
|---|---|---|---|---|---|---|
| AEZS | AEterna Zentaris | 0.71 | -0.02 | -3.04% | 86.2M |
AEterna Zentaris Frequently Asked Questions
Q
How do I buy AEterna Zentaris (AEZS) stock?
A
You can purchase shares of AEterna Zentaris (NASDAQ: AEZS) through any online brokerage.
Q
Who are AEterna Zentaris's (AEZS) competitors?
A
There are no as such competitors for AEterna Zentaris.
Q
What is the target price for AEterna Zentaris (AEZS) stock?
A
The latest price target for AEterna Zentaris (NASDAQ: AEZS) was reported by Maxim Group on June 15, 2018. The analyst firm set a price target for 0.00 expecting AEZS to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
Q
Current Stock Price for AEterna Zentaris (AEZS)?
A
The stock price for AEterna Zentaris (NASDAQ: AEZS) is $0.7118 last updated Today at 4:59:00 PM.
Q
Does AEterna Zentaris (AEZS) pay a dividend?
A
There are no upcoming dividends for AEterna Zentaris.
Q
When is AEterna Zentaris (NASDAQ:AEZS) reporting earnings?
A
AEterna Zentaris’s Q2 earnings are confirmed for after-market on August 5, 2021.
Q
Is AEterna Zentaris (AEZS) going to split?
A
There is no upcoming split for AEterna Zentaris.
Q
What sector and industry does AEterna Zentaris (AEZS) operate in?
A
AEterna Zentaris is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.